Telaprevir
- Generic Name
- Telaprevir
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C36H53N7O6
- CAS Number
- 402957-28-2
- Unique Ingredient Identifier
- 655M5O3W0U
- Background
Telaprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of...
- Indication
Telaprevir, when used in combination with Ribavirin, Peginterferon alfa-2a, and Peginterferon alfa-2b is indicated for use in the treatment of chronic HCV genotype 1 infection in adults .
- Associated Conditions
- Chronic Hepatitis C Genotype 1
- Associated Therapies
- -
Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)
- Conditions
- Interventions
- First Posted Date
- 2013-04-01
- Last Posted Date
- 2020-09-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT01821963
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Drug Interaction Study of the Effects of PPI-668 on the Pharmacokinetics of Midazolam and Omeprazole
- Conditions
- Interventions
- First Posted Date
- 2013-02-08
- Last Posted Date
- 2013-03-26
- Lead Sponsor
- Presidio Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01786382
- Locations
- 🇺🇸
Spaulding Clinical Research, West Bend, Wisconsin, United States
Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers
- First Posted Date
- 2013-01-11
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- Massachusetts General Hospital
- Registration Number
- NCT01766115
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects
- Conditions
- Interventions
- First Posted Date
- 2012-10-31
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 258
- Registration Number
- NCT01718145
- Locations
- 🇯🇵
Local Institution, Saitama, Japan
Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy
- Conditions
- Interventions
- First Posted Date
- 2012-10-31
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 444
- Registration Number
- NCT01718158
- Locations
- 🇺🇸
Nashville Medical Research Institute, Nashville, Tennessee, United States
🇺🇸Va Long Beach Healthcare System, Long Beach, California, United States
🇬🇧Local Institution, London, Greater London, United Kingdom
Viral Kinetics in HCV Clearance in Subjects With Hemophilia
- Conditions
- Interventions
- First Posted Date
- 2012-10-11
- Last Posted Date
- 2015-04-06
- Lead Sponsor
- Kenneth Sherman
- Target Recruit Count
- 5
- Registration Number
- NCT01704521
- Locations
- 🇺🇸
UC Physicians Company, Cincinnati, Ohio, United States
An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus
- Conditions
- Interventions
- First Posted Date
- 2012-10-04
- Last Posted Date
- 2016-07-20
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 42
- Registration Number
- NCT01701063
Eltrombopag/Boceprevir and Eltrombopag/Telaprevir Drug-Drug Interaction Study In Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2012-08-06
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 56
- Registration Number
- NCT01657552
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
Dose Ranging of GSK2336805 in Combination Therapy
- Conditions
- Interventions
- First Posted Date
- 2012-07-24
- Last Posted Date
- 2017-06-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 286
- Registration Number
- NCT01648140
- Locations
- 🇵🇷
GSK Investigational Site, San Juan, Puerto Rico
Drug Interaction Study to Assess the Effect of Co-Administered Miravirsen and Telaprevir in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2012-11-12
- Lead Sponsor
- Santaris Pharma A/S
- Target Recruit Count
- 5
- Registration Number
- NCT01646489
- Locations
- 🇺🇸
Spaulding Clinical Research, West Bend, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.